|  |
| --- |
| Supplementary Table 1 - Clinical characteristics of patients at the time of LT in the different subgroups considered (Nivolumab/Bevacizumab, Tyrosine Kinase Inhibitors – TKI, or Best Supportive Care - BSC). |
| **Features**  | **All****(n=22)** | **Nivo/Beva****(n=5)** | **TKIs****(n=13)** | **BSC****(n=4)** | **p** |
| **Age (mean, SD)** | 59.1 ±7.9 | 55.8±7.6 | 60.2 ± 9.1 | 60 ± 2.8 | 0.791 |
| **Gender (male, %)**  | 17 (77.3) | 3 (60.0) | 11 (91.7) | 3 (75.0) | 0.211 |
| **Blood type** |  |  |  |  |  |
|  A B AB 0 | 7 (31.8)4 (18.1) 2 (9.0)9 (40.9) | 2 (40.0)--3 (60.0) | 5 (38.4)2 (15.3)2 (15.3)4 (30.7) | 1 (25.0)2 (50.0)-1 (25.0) | 0.466 |
| **Etiology of Liver disease (n, %)*** HCV
* HBV
* Other causes
 | 10 (45.5)7 (31.8)5 (22.7) | 2 (40.0)1 (20.0)2 (40.0) | 6 (46.2)4 (30.7)3 (23.1) | 2 (50.0)2 (50.0)0 | 0.821 |
| **Edmondson-Steiner grading (n, %)** |  |  |  |  |  |
|  **1** |  |  | 1 (7.7) |  |  |
|  2 | 10 (45.4) | 3 (75.0) | 6 (46.15) | 0 | 0.114 |
|  3 | 12 (54.5) | 1(25.0) | 6 (46.15) | 4 (100.0) |
| **Bilirubin (mg/dL)(mean, SD)** | 0.5±0.2 | 0.56 ± 0.25 | 0.45 ± 0.15 | 0.61 ± 0.26 | 0.441 |
| **Albumin (g/dL)(mean, SD)** | 3.8±0.43 | 3.9 ± 0.54 | 3.7 ± 0.40 | 4 ± 0.42 | 0.249 |
| **AFP (ng/mL)(mean, SD)** | 138±326 | 43 ± 35 | 149 ± 403 | 273 ± 242 | 0.118 |
| **Down staged before LT** | 21 (95.4) | 5 (29.4) | 10 (58.8) | 2 (11.8) | 0.157 |
| **Pre-transplant downstaging modalities (n, %)*** None
* Resection
* Loco-regional treatments
* Combined
 | 5 (22.7)4 (18.1)9 (40.9)4 (18.1) | 01 (20.0)3 (60.0)1 (20.0) | 2 (15.4)3 (23.1)5 (38.4) 3 (23.1) | 3 (75.0)0 1 (25.0)0 | 0.125 |
| **“Milan-in” at LT time (n, %)** | 17 (77.3) | 4 (80.0) | 9 (75.0) | 4 (80.0) | 0.962 |
| **Presence of viable tumor at explant (n, %)** | 17 (77.2) | 3 (60.0) | 10 (76.9) | 4 (100.0) | 0.295 |
| **Presence of extra-hepatic tumor at LT (n, %)** | 5 (13.6) | 2 (20.0) | 1 (7.6) | 2 (11.8) | 0.365 |
| **Re-transplant (n, %)** | 2 (9.0) | 1 (20.0) | 1 (7.6) | - | 0.577 |
| **Immunosuppressive regimen at transplant (n, %)*** Everolimus
* Sirolimus
* Tacrolimus
* Mycophenolate
 | 12 (54.5)5 (22.7)4 (18.1)1 (4.5) | 3 (60.0)2 (40.0) | 6 (46.1)2 (46.1)3 (23.0)1 (7.7) | 3 (75.0)1 (25.0)1 (25.0) | 0.369 |